Ethical and Epidemiological Dimensions of Labeling Psychosis Risk.
The past two decades have marked an increase in research on the prodromal stages of schizophrenia that precede a first episode of psychosis. Criteria for a clinical high risk (CHR) state for psychosis have been validated and included in the DSM-5 as the attenuated psychosis syndrome and as requiring further study. This was hotly debated, given the concern of stigmatizing young people who would receive this psychosis risk label. In this article, I review ethical issues related to the psychosis risk label, including the potential harm of stigma and paternalism if risk labels are withheld in the context of the observed low predictive power of the psychosis risk designation. I review data that supports that the psychosis risk label need not be harmful, and could even confer benefit, and set out strategies for reducing stigma through individualized risk assessment and public health education.
Research faculty in the Department of Psychiatry at the New York State Psychiatric Institute (NYSPI) at Columbia University Medical Center in New York City.
Cheryl M
CM
Corcoran
D003142:Communication; D030881:Disclosure / Q000941:ethics*; D004992:Ethics, Medical; D006801:Humans; D062706:Prodromal Symptoms; D011618:Psychotic Disorders / Q000175:diagnosis; D012559:Schizophrenia / Q000175:diagnosis; D057545:Social Stigma; D013240:Stereotyping